Back to top
more

Surmodics (SRDX)

(Delayed Data from NSDQ)

$37.66 USD

37.66
184,435

+0.09 (0.24%)

Updated Nov 5, 2024 04:00 PM ET

After-Market: $37.66 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Here's Why You Should Invest in Veeva Systems (VEEV) Now

by Zacks Equity Research

Veeva Systems' (VEEV) focus on cloud-based systems like Veeva Vault makes it a solid pick.

Hill-Rom-Microsoft Tie-Up to Widen Digital Solutions Suite

by Zacks Equity Research

Hill-Rom (HRC) progresses with efforts to gain traction in the digital health space.

Integra (IART) Rises 5% on Robust Preliminary Q4 Results

by Zacks Equity Research

Integra's (IART) total Q4 revenues are likely to be at the upper end of its prior guided range.

Boston Scientific Gains on Impressive Preliminary Q4 Results

by Zacks Equity Research

Boston Scientific's (BSX) solid top line is expected to be backed by growth across all segments and geographical regions in Q4.

ResMed Announces Complete Mobi Launch in US Markets for COPD

by Zacks Equity Research

ResMed (RMD) progresses with efforts to boost Respiratory Care suite.

QIAGEN Scores on Strategic Alliances, Suffers Low HPV Sales

by Zacks Equity Research

QIAGEN (QGEN) pins high hopes on its strategic tie-ups with Hamilton and DiaSorin. It unveils a CE-marked DiaSorin automation solution in Europe to use the LIAISON system for test read-out.

Hologic Stock Rides on Impressive Preliminary Q1 Result

by Zacks Equity Research

Hologic's (HOLX) strong top line is primarily expected on the back of balanced growth across a majority of the company's segments in Q1.

ResMed Closes Propeller Health Buyout, Boosts COPD Suite

by Zacks Equity Research

ResMed (RMD) expects to boost the Respiratory Care suite with the recently-completed Propeller Health buyout.

Cardiovascular Systems Expands Portfolio Amid Stiff Rivalry

by Zacks Equity Research

Cardiovascular Systems (CSII) continues to expand its portfolio to widen the company's reach. However, Cardiovascular Systems operating in a highly competitive environment is a concern.

Neogen's Canadian Lab Buyout to Boost Genomics Business

by Zacks Equity Research

Neogen (NEOG) continues to adopt initiatives to boost the genomics business.

LabCorp Rides on Covance Business Amid Reimbursement Woes

by Zacks Equity Research

Within Covance Drug Development business, LabCorp (LH) aims at reaping huge profits via expanded solutions and better operational skills.

Omnicell (OMCL) Rides on Innovation Despite Cost Concerns

by Zacks Equity Research

Omnicell (OMCL) steadily sees a solid uptake of Omnicell XT. It also strikes various deals for the XR2 and IVX Workflow products.

LabCorp, GENFIT Tie-Up to Develop Test for NASH, Widen Suite

by Zacks Equity Research

LabCorp (LH) continues to strengthen foothold in the diagnostics space through organic and inorganic means.

Here's Why You Should Add CVS Health to Your Portfolio Now

by Zacks Equity Research

CVS Health (CVS) is optimistic about synergies from Aetna deal which will help create a robust platform to serve individuals better.

Solid Global Business Aids NuVasive Amid Pricing Pressure

by Zacks Equity Research

Per NuVasive (NUVA), the international region holds significant growth opportunity. However, pricing pressure is a major headwind.

Cardiovascular Systems Gets Approvals in Japan, Widens Suite

by Zacks Equity Research

Cardiovascular Systems (CSII) continues to expand product portfolio to enhance market reach and versatility.

Sreyoshi Mukherjee headshot

Has the Trade Debacle Ended for US MedTech Space? 3 Picks

by Sreyoshi Mukherjee

As the trade war fears slowly dissipate, let's take a look at three profitable U.S. MedTech picks.

Here's Why You Should Add Amedisys (AMED) to Your Portfolio

by Zacks Equity Research

Amedisys (AMED) is developing and acquiring new business lines that will complement its existing home care and hospice business.

Walgreens Counts on International Progress, Strategic Deals

by Zacks Equity Research

We are upbeat about Walgreens' (WBA) recent pact with Alphabet???s life sciences and healthcare segment, Verily, to coordinate on multiple projects with respect to chronic ailments.

Cardiovascular Systems Treats First Patient With Teleport

by Zacks Equity Research

Cardiovascular Systems (CSII) expands product portfolio to enhance market reach and versatility.

Here's Why You Should Invest in Hill-Rom (HRC) Stock Now

by Zacks Equity Research

Hill-Rom's (HRC) M&A pipeline continues to be strong.

Boston Scientific (BSX) to Buy Residual Shares of Millipede

by Zacks Equity Research

Boston Scientific's (BSX) buyout of the leftover stake in Millipede will integrate the latter's IRIS Transcatheter Annuloplasty Ring System in the Structural Heart portfolio of the former.

Zimmer Biomet (ZBH) Thrives on New Projects, APAC Growth

by Zacks Equity Research

Zimmer Biomet (ZBH) is performing well on the back of its two largest commercial projects, namely the Persona Revision system and the Rosa robotics knee application.

Medtronic's Growth Across All Lines Aid, Rising Costs Ail

by Zacks Equity Research

Of late, Medtronic (MDT) succeeds in delivering solid top-line growth at CER, backed by balanced growth across major business operation.

Myriad Genetics Posts Positive Adjusted Vectra Test Data

by Zacks Equity Research

The key finding of Myriad Genetics' (MYGN) study proves that the adjusted Vectra score beats all traditional measures of disease activity to predict radiographic progression in RA patients.